एमक्युअर फार्मास्युटिकल्स शेअर किंमत

इंटरनॅशनल मार्केटमध्ये मजबूत कामगिरी आणि एम्क्युअरच्या इन-हाऊस पोर्टफोलिओमधून नवीन लाँचमध्ये वाढ झाल्यामुळे नफ्यात वाढ झाली

• बिझनेस स्टँडर्ड
• 1 महिना 1 आठवड्यापूर्वी

Q4FY26 परफॉर्मन्स आणि आऊटलुकवर एमक्युअर फार्मास्युटिकल्स मॅनेजमेंट आणि ॲनालिस्टसह कॉन्फरन्स कॉल. पूर्ण कमाईची ट्रान्सक्रिप्ट ऐका.

• ट्रेंडलाईन
• 1 महिना 1 आठवड्यापूर्वी

Pharmaceuticals company Emcure Pharmaceuticals announced Q4FY26 & FY26 results Q4FY26 Financial Highlights: Revenue from operations at Rs 2,470 crore, up 16.7% YoY. EBITDA at Rs 485 crore up 24.5% YoY, EBITDA margins at 19.7%. Reported PAT at Rs 244 crore, up 23.6% YoY. Adj. PAT2 at Rs 279 crore, up by 36.0% YoY. Domestic business sales at Rs 977 crore, up 5.2% YoY. Softer performance largely due to the Zuventus portfolio and team reorganization. International business sales at Rs 1,493 crore, up 25.7% YoY with strong growth across markets supported by base business ramp up and new launches. FY26 Financial Highlights: Revenue from operations at Rs 9,204 crore, up 16.6% YoY, ahead of stated guidance. EBITDA at Rs 1,789 crore up 21.8% YoY, EBITDA margins at 19.4%. Reported PAT at Rs 941 crore, up 33.1% YoY. Adj. PAT2 at Rs 1,008 crore, up by 40.9% YoY. Domestic business sales at Rs 4,027 crore, up 10.0% YoY. Growth in-line with market, led by cardiac, CNS and oncology. Consolidated domestic operations with subsidiary minority stake buyout, strengthened leadership teams across divisions and expanded portfolio via key MNC partnerships. International business sales at Rs 5,177 crore, up 22.2% YoY. Strong momentum from base business growth and new launches from in-house portfolio. Satish Mehta, CEO & Managing Director, Emcure Pharmaceuticals, said: "In FY26, the first year of our five-year strategic plan, Emcure delivered strong financial performance with over USD 1 billion in revenue and 16.6% growth. International markets demonstrated robust momentum while our domestic business recorded steady growth. We delivered ~41% adjusted PAT growth in the year. We strategically expanded through in-licensing, Zuventus minority buyout and bolt-on acquisitions in the UK and Canada. Our R&D; pipeline in complex injectables and biosimilars remains a key driver of future value. Our priorities remain clear - to deliver sustainable, above-industry growth and consistent margin expansion, while continuing to build sustainable long-term value for all stakeholders.” Result PDF

• ट्रेंडलाईन
• 1 महिना 1 आठवड्यापूर्वी